Navigation Links
Edwards, Medtronic and Boston Scientific Lead Market Growth for Cardiac Surgery, Cardiac Rhythm Management and Interventional Cardiology Devices, Reports iData Research, Inc.
Date:10/29/2013

Vancouver, BC (PRWEB) October 29, 2013

iData Research, the leading global authority in medical device and pharmaceutical market research, has published a new report series for the U.S. Cardiology Device Markets. Cardiovascular disease is much more prevalent among patients over 55 years of age; therefore as the U.S. population ages, the incidence of cardiovascular disease will increase. In addition, rising rates of obesity will also contribute to the incidence of heart disease. As the baby boomer generation in the U.S. ages, the patient population will increase. This increase in the patient population will lead to an annual 3% to 4% increase in the number of patients requiring some type of arrhythmia treatment.

The fastest growing market among cardiac rhythm management, electrophysiology and ablation devices is diagnostic electrophysiology catheters. This market grew due to the increased use of Intracardiac Echography (ICE) and electrophysiology mapping catheters. The high average selling price of these products also bolstered market growth. Top competitors include Medtronic, St. Jude Medical and Boston Scientific.

The fastest growing areas of the cardiac surgery market will be that of transcatheter heart valve devices. These devices are used for repairing and replacing heart valves without the need for open surgery. They are expected to be widely accepted as new devices continue to be approved by the Food and Drug Administration (FDA). “The THVI market is expected to increase to represent over 15% of the total cardiac surgery market by 2019,” says Dr. Kamran Zamanian, CEO of iData. Competitors such as Edwards LifeSciences, Medtronic and Maquet together hold nearly half of the total market for cardiac surgery devices.

The U.S. market for interventional cardiology devices was valued at over $3.5 billion, with drug-eluting stents comprising the largest segment of the market, followed by coronary vascular closure devices, PTCA and cutting balloon catheters, bare-metal stents, intravascular ultrasound (IVUS) catheters, coronary introducer sheaths, interventional coronary guidewires, coronary embolic protection devices, interventional coronary catheters and balloon-inflation syringes. The report states that over the forecast period, the U.S. market for interventional cardiology is expected to exceed $4.2 billion by 2019 led by companies such as Boston Scientific, Abbott Laboratories, and St. Jude Medical. Market growth is expected to be tied to growth of the drug-eluting stent market and the expansion of the optical coherence tomography (OCT) catheter market.

In Addition to the U.S. cardiology report series, iData has research for the following countries: Japan, South Korea, China, India and Australia, Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, U.K.

For a free report synopsis, click here.

About iData Research

iData Research is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: infusion therapy, peripheral vascular, vascular-access, drug-delivery and more.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11278478.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Potential Medtronic Infusion Pump Malfunction Claims: Resource4thePeople Attorneys Now Providing Consulations
2. Medtronic Infuse Bone Graft Lawsuit Help: Resource4thePeople Reports New Court Ruling in Favor of Plaintiffs
3. Lawsuit Against Medtronic Inc. Will Proceed, as Judge Rejects Device Maker's Preemption Arguments to Have Medtronic Infuse Case Dismissed, Parker Waichman LLP Reports
4. Arizona Judge Rejects Medtronic Inc.'s Efforts to Dismiss a Lawsuit That Alleges the Company Promoted Off-Label Use of Its Infuse Bone Graft Product, Parker Waichman LLP Reports
5. Judge Denies Medtronic’s Bid to Dismiss Lawsuit Alleging that the Off-Label Usage of its Infuse Bone Growth Product Caused Disability, Parker Waichman LLP Notes
6. Access MediQuip's Rapid Response To Medtronic Infusion Pump Recall Protects Patients
7. Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments
8. Medtronic Neurostimulator: An Implantable Device Grants Warren Man New Lease on Life
9. Medtronic's InFuse Under Intense Scrutiny and Class Action Lawsuit
10. Medtronic Infuse Bone Graft Failure Allegation Lawsuits Update: New Legal Consultations Available Over Alleged Medical Malpractice
11. Medtronic Infuse Lawsuit News: Parker Waichman LLP Alerts the Public to the June Release of Yale’s Infuse Bone Graft Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths ... Assembly Bill (AB) 1512, which proposes a tax on prescription opioids to fund ...
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
(Date:3/24/2017)... Dallas, Texas (PRWEB) , ... March 24, 2017 , ... ... Budget Office score is invalid because it does not obey the rules Congress has ... million full-time equivalent jobs, which the GOP reform would restore. Yet, it estimates a ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly ... announced plans to invest $850 million in its ... facilities across its U.S. enterprise, including research laboratories, ... investments are being driven by demand for Lilly ... potential medicines in development targeting cancer, pain, diabetes ...
Breaking Medicine Technology: